RHC-80267 (U-57908)
DAG Lipase inhibitor / Inhibits DAG Lipase activity in a variety of cell types and tissues, including canine platelets, bovine adrenal chromaffin cells, human adrenal glomerulosa cells, rat thyroid lobes and pancreatic minilobules. IC50 in canine platelets is 4 µM1.
Biochemicals & reagents
83654-05-1
U-57908
1) Southerland and Amin (1982), Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors; J. Biol. Chem., 257 14006 / 2) Rindlisbacher et al. (1990), Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis; J. Neurochem, 54 1247 / 3) Chandra Sekar et al. (1987), Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors; Arch. Biochem. Biophys., 256 509 / 4) Levasseur et al. (1984), Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis; Prostaglandins, 27 673 / 5) Natarajan et al. (1988), Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors; Biochem. Biophys. Res. Commun., 156 717
RT
TARGET: Lipase -- PATHWAY: Coagulation; Fatty acid metabolism; Lipid signaling; cAMP / cGMP signaling; Coagulation -- DISEASE AREA: Diabetes